^
BIOMARKER:

HLA-A2 positive

i
Other names: HLA-A, Major Histocompatibility Complex, Class I, A, HLA Class I Histocompatibility Antigen, A Alpha Chain, HLAA, HLA Class I Histocompatibility Antigen, A-1 Alpha Chain, MHC Class I Antigen HLA-A Heavy Chain, Leukocyte Antigen Class I-A, Human Leukocyte Antigen A
Entrez ID:
Related biomarkers:
Phase 1
TScan Therapeutics, Inc.
Recruiting
Last update posted :
08/03/2022
Initiation :
08/01/2022
Primary completion :
12/01/2024
Completion :
06/01/2025
HLA-A
|
HLA-A2 positive • HLA-A*02 • HLA-A positive
|
melphalan • TSC-100 • TSC-101
Phase 2
Adaptimmune
Recruiting
Last update posted :
07/18/2022
Initiation :
09/15/2021
Primary completion :
04/01/2023
Completion :
10/01/2038
HLA-A • MAGEA4
|
HLA-A2 positive • HLA-A*02 • MAGEA4 expression
|
ADP-A2M4CD8 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Nicholas Butowski
Active, not recruiting
Last update posted :
07/18/2022
Initiation :
04/03/2017
Primary completion :
12/31/2022
Completion :
12/31/2022
CD8 • CD4
|
HLA-A2 positive
|
Hiltonol (poly-ICLC) • IMA950 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • varlilumab (CDX 1127)
Phase 2
Adaptimmune
Recruiting
Last update posted :
06/30/2022
Initiation :
08/13/2019
Primary completion :
01/01/2023
Completion :
11/01/2034
HLA-A • MAGEA4
|
HLA-A2 positive • HLA-A*02 • MAGEA4 expression
|
afamitresgene autoleucel (ADP-A2M4) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 3
Greenwich LifeSciences, Inc.
Not yet recruiting
Last update posted :
06/30/2022
Initiation :
07/01/2022
Primary completion :
12/01/2026
Completion :
12/01/2026
HER-2 • HLA-A
|
HLA-A2 positive • HLA-A*02
|
Herceptin (trastuzumab) • GLSI-100 • GP2 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
University of Washington
Active, not recruiting
Last update posted :
06/21/2022
Initiation :
05/01/2016
Primary completion :
03/31/2021
Completion :
09/30/2023
HER-2 • IFNG
|
HER-2 overexpression • HER-2 amplification • HER-2 expression • HLA-A2 positive
|
Herceptin (trastuzumab) • HER-2/neu peptide vaccine
Phase 1
Jeremy Rudnick, M.D
Not yet recruiting
Last update posted :
04/22/2022
Initiation :
06/01/2022
Primary completion :
06/01/2023
Completion :
06/01/2025
HER-2 • CD133 • IL13RA2
|
HLA-A2 positive • CD133 expression
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • KROS-201
Phase 1
GlaxoSmithKline
Recruiting
Last update posted :
04/22/2022
Initiation :
12/21/2020
Primary completion :
02/13/2024
Completion :
02/13/2024
BRAF • PD-L1 • ALK • ROS1 • HLA-A • CTAG1B • CTAG2
|
HLA-A*02:01 • HLA-A2 positive • HLA-A*02 • CTAG2 expression
|
cyclophosphamide • fludarabine IV • GSK3845097 • GSK3901961 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • LYL132
Phase 2
OncoPep, Inc.
Not yet recruiting
Last update posted :
04/20/2022
Initiation :
04/30/2022
Primary completion :
04/01/2023
Completion :
04/01/2025
PD-L1
|
PD-L1 expression • HLA-A2 positive
|
Keytruda (pembrolizumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • PVX-410
Phase 1/2
Sabine Mueller, MD, PhD
Active, not recruiting
Last update posted :
04/20/2022
Initiation :
11/18/2016
Primary completion :
11/30/2024
Completion :
11/30/2024
HLA-A
|
H3.3K27M • HLA-A*02:01 • HLA-A2 positive • HLA-A*02
|
Opdivo (nivolumab) • Hiltonol (poly-ICLC) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
02/21/2022
Initiation :
12/01/2016
Primary completion :
12/01/2022
Completion :
12/01/2023
HLA-A
|
HLA-A2 positive • HLA-A*02
|
DPX-E7 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
GlaxoSmithKline
Recruiting
Last update posted :
02/16/2022
Initiation :
12/31/2019
Primary completion :
11/30/2022
Completion :
07/31/2026
HLA-A • CTAG1B
|
HLA-A*02:01 • HLA-A2 positive • HLA-A*02 • CTAG1B expression
|
cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Adaptimmune
Withdrawn
Last update posted :
11/16/2021
Initiation :
07/02/2020
Primary completion :
12/01/2021
Completion :
12/01/2021
HLA-A • MAGEA4
|
HLA-A2 positive • HLA-A*02 • MAGEA4 expression
|
Keytruda (pembrolizumab) • afamitresgene autoleucel (ADP-A2M4) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Medigene AG
Withdrawn
Last update posted :
10/08/2021
Initiation :
07/02/2020
Primary completion :
07/01/2023
Completion :
07/01/2025
CD8 • HLA-A
|
HLA-A*02:01 • HLA-A2 positive • HLA-A*02
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Adaptimmune
Active, not recruiting
Last update posted :
10/05/2021
Initiation :
07/05/2017
Primary completion :
09/01/2032
Completion :
09/01/2035
HLA-A • MAGEA4
|
HLA-A2 positive • HLA-A*02
|
afamitresgene autoleucel (ADP-A2M4) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Ludwig Institute for Cancer Research
Completed
Last update posted :
09/15/2021
Initiation :
06/23/2003
Primary completion :
05/09/2006
Completion :
08/01/2013
CD8 • CTAG1B • MUC16
|
HLA-A2 positive
Phase 1
Ian F. Pollack, M.D.
Active, not recruiting
Last update posted :
08/10/2021
Initiation :
02/01/2009
Primary completion :
12/31/2022
Completion :
12/31/2023
IFNG
|
HLA-A2 positive
|
Hiltonol (poly-ICLC)
Phase 1
Ludwig Institute for Cancer Research
Completed
Last update posted :
07/15/2021
Initiation :
09/03/2003
Primary completion :
09/05/2005
Completion :
06/06/2006
CD8 • CTAG1B • CTAG2
|
HLA-A2 positive
|
Promune (agatolimod)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
07/02/2021
Initiation :
06/14/2016
Primary completion :
07/22/2019
HER-2
|
HER-2 expression • HLA-A2 positive
|
HER-2/neu peptide vaccine • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • Leukine (sargramostim) • NeuVax (nelipepimut-S)
Phase 1b
Massachusetts General Hospital
Active, not recruiting
Last update posted :
05/10/2021
Initiation :
08/01/2016
Primary completion :
12/01/2021
Completion :
09/01/2022
HER-2 • ER • PGR
|
HER-2 negative • HLA-A2 positive
|
Imfinzi (durvalumab) • Hiltonol (poly-ICLC) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • PVX-410
Phase 1/2
Radboud University
Completed
Last update posted :
04/01/2021
Initiation :
01/01/2016
Primary completion :
03/31/2021
Completion :
03/31/2021
ABL1 • BCR • CD8
|
HLA-A2 positive
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Roswell Park Cancer Institute
Completed
Last update posted :
11/03/2020
Initiation :
09/01/2009
Primary completion :
10/05/2018
Completion :
10/05/2019
CD8 • CD4
|
HLA-A2 positive
|
goserelin acetate
Phase 1
Centre Hospitalier Universitaire Vaudois
Completed
Last update posted :
06/19/2020
Initiation :
02/01/2004
Primary completion :
03/01/2013
Completion :
03/01/2013
CD8 • IFNG • TNFA • CTAG1B • CD4 • MLANA • CTAG2
|
HLA-A2 positive
Phase 2
San Antonio Military Medical Center
Completed
Last update posted :
03/30/2020
Initiation :
01/01/2007
Primary completion :
12/31/2014
Completion :
03/31/2017
HER-2 • ER • PGR • CSF2
|
HER-2 amplification • HER-2 expression • HLA-A2 positive • PGR negative
|
AE 37 • GLSI-100 • Leukine (sargramostim)
Phase 1/2
Medigene AG
Recruiting
Last update posted :
01/09/2020
Initiation :
03/27/2018
Primary completion :
08/01/2020
Completion :
04/01/2024
HLA-A • PRAME
|
PRAME expression • HLA-A*02:01 • HLA-A2 positive • HLA-A*02
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • MD 101 • MDG1011
Phase 1/2
University of Pennsylvania
Completed
Last update posted :
10/23/2019
Initiation :
08/01/2005
Primary completion :
08/01/2008
Completion :
08/01/2008
HER-2 • MUC16
|
HLA-A2 positive
|
cyclophosphamide
Phase 1
Ian F. Pollack, M.D.
Completed
Last update posted :
08/30/2019
Initiation :
01/01/2009
Primary completion :
02/01/2013
Completion :
07/01/2015
IFNG
|
HLA-A2 positive
|
Hiltonol (poly-ICLC)
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
04/15/2019
Initiation :
07/21/2004
Primary completion :
04/01/2018
Completion :
05/31/2018
CEACAM5
|
MUC1 expression • HLA-A2 positive
|
Leukine (sargramostim) • Panvac-VF (falimarev/inalimarev)
Phase 1
Mayo Clinic
Completed
Last update posted :
02/19/2019
Initiation :
03/01/2007
Primary completion :
04/01/2009
Completion :
01/02/2013
CD19 • CD14
|
HLA-A2 positive
|
Proleukin (aldesleukin) • Leukine (sargramostim)
Phase 1
Mayo Clinic
Completed
Last update posted :
10/31/2018
Initiation :
08/28/2008
Primary completion :
04/21/2015
Completion :
04/21/2015
HER-2 • CD8 • IFNG • MUC1 • CD4 • IL5
|
HER-2 overexpression • HER-2 amplification • HLA-A2 positive • PGR expression
|
HER-2/neu peptide vaccine • Leukine (sargramostim)
Phase 1/2
Frank Lieberman
Completed
Last update posted :
02/07/2018
Initiation :
12/01/2006
Primary completion :
09/01/2009
Completion :
06/01/2016
ALK
|
HLA-A2 positive
Phase 3
immatics Biotechnologies GmbH
Completed
Last update posted :
10/12/2017
Initiation :
12/01/2010
Primary completion :
07/01/2015
Completion :
07/01/2015
HLA-A
|
HLA-A2 positive • HLA-A*02
|
Sutent (sunitinib) • cyclophosphamide • IMA-901 • Leukine (sargramostim)
Phase 2
Pawel Kalinski
Withdrawn
Last update posted :
09/26/2017
Initiation :
03/01/2016
Primary completion :
06/01/2018
Completion :
12/01/2018
KRAS
|
KRAS wild-type • RAS wild-type • HLA-A2 positive
|
Ampligen (rintatolimod) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • celecoxib oral
Phase 1/2
University Hospital Tuebingen
Unknown status
Last update posted :
08/17/2017
Initiation :
04/01/2004
Primary completion :
10/01/2017
Completion :
10/01/2017
HLA-A
|
HLA-A2 positive • HLA-A*02
|
Zyclara (imiquimod) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2b
ImmunoCellular Therapeutics, Ltd.
Completed
Last update posted :
03/20/2017
Initiation :
01/01/2011
Primary completion :
12/01/2013
Completion :
12/01/2015
MGMT
|
HLA-A2 positive
|
ICT-107
Phase 1
Shenzhen Second People's Hospital
Unknown status
Last update posted :
08/03/2016
Initiation :
04/01/2015
Primary completion :
12/01/2019
Completion :
12/01/2019
CTAG1B
|
HLA-A2 positive • CTAG1B expression
|
cyclophosphamide • fludarabine IV • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 0
Washington University School of Medicine
Withdrawn
Last update posted :
07/18/2016
Initiation :
07/01/2016
Primary completion :
10/01/2019
Completion :
10/01/2023
CD8
|
HLA-A2 positive
|
cyclophosphamide • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Cancer Research UK
Completed
Last update posted :
10/14/2015
Initiation :
07/01/2010
Primary completion :
02/01/2015
Completion :
02/01/2015
MGMT • HLA-A • CSF2
|
HLA-A2 positive • HLA-A*02
|
temozolomide • IMA950 • Leukine (sargramostim)
Phase 1
M.D. Anderson Cancer Center
Withdrawn
Last update posted :
03/04/2014
Initiation :
03/01/2008
Primary completion :
03/01/2015
ABL1 • BCR
|
HLA-A2 positive • BCR expression
Phase N/A
National Cancer Institute (NCI)
Completed
Last update posted :
06/20/2013
Initiation :
08/01/2004
Completion :
02/01/2006
CEACAM5
|
CEACAM5 positive • HLA-A2 positive
|
carboplatin • paclitaxel
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
06/19/2013
Initiation :
09/01/2002
Completion :
10/01/2007
ER • PGR • CEACAM5
|
HLA-A2 positive
|
paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Leukine (sargramostim)
Phase 1/2
immatics Biotechnologies GmbH
Completed
Last update posted :
05/16/2013
Initiation :
06/01/2008
Primary completion :
01/01/2011
Completion :
05/01/2013
HLA-A
|
HLA-A2 positive • HLA-A*02
|
cyclophosphamide • oxaliplatin • Zyclara (imiquimod) • IMA910 • Leukine (sargramostim)
Phase 1
Centre Hospitalier Universitaire Vaudois
Completed
Last update posted :
04/24/2013
Initiation :
05/01/1999
Primary completion :
06/01/2007
Completion :
06/01/2007
MLANA • MAGEA10
|
HLA-A2 positive
Phase 1
Centre Hospitalier Universitaire Vaudois
Completed
Last update posted :
04/22/2013
Initiation :
04/01/2003
Primary completion :
08/01/2011
Completion :
06/01/2012
MLANA
|
HLA-A2 positive
|
Promune (agatolimod)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
01/23/2013
Initiation :
03/01/2005
Primary completion :
09/01/2007
CD8
|
HLA-A2 positive
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Prof. Serge Leyvraz
Completed
Last update posted :
11/20/2012
Initiation :
09/01/2005
Primary completion :
11/01/2011
CD8 • MLANA
|
HLA-A2 positive
|
cyclophosphamide • ImmuFact (eftilagimod alpha) • fludarabine IV